Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Br J Haematol. 2016 Dec 19;176(5):759–769. doi: 10.1111/bjh.14480

Figure 1. Study schema.

Figure 1

Ara-C = cytarabine; BEAM = carmustine [BCNU]/etoposide/cytarabine/melphalan; CBV = carmustine [BCNU], cyclophosphamide, etoposide; Cy, cyclophosphamide; HCVAD = ; HyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone, alternating with high dose cytarabine and methotrexate) MTX, = methotrexate; PR = partial response; R = rituximab; TBI = total body irradiation; VP16 = etoposide.